Nov 3 (Reuters) - Surgical devices and orthopedic care company Integra LifeSciences Holdings Corp said it would spin off its spine unit in an attempt to streamline its operations.
LONDON, Oct 30 (Reuters) - Artificial knee and hip maker Smith & Nephew posted an expected 3 percent rise in third-quarter trading profit, as solid growth in orthopaedic reconstruction offset a decline in its wound management business due to a product recall.
Zimmer reported solid third-quarter results that ..... currency. Thanks to a tight rein on expenses, Zimmer is on track to meet our estimates for operating ..... quarter, including dental and surgical, Zimmer saw healthy growth in its large joints
BRUSSELS, Oct 10 (Reuters) - European Union antitrust regulators will decide on U.S. medical device maker Zimmer 's $13.4 billion bid for Biomet by March 11, a three-week extension from the previous deadline, the European Commission said on Friday.
have less influence on brand decisions compared with highly engineered, implantable devices. Unlike St. Jude Medical and Zimmer 's devices, Bard's products are generally more vulnerable to pricing pressure. However, Bard's products are also typically
generate cash over the longer term. As the orthopedic market continues to consolidate, we ..... As one of the last standing midtier orthopedic companies, Smith & Nephew presents ..... particular, S&N enjoyed more robust orthopedic implant growth in the U.S., which
Zimmer posted soft second-quarter performance ..... revenue growth of 1% in constant currency, Zimmer trailed rivals Stryker and Johnson & Johnson's DePuy business. In recent quarters, Zimmer has benefited from the introduction of its
intangible assets source, there also are switching costs. Switching costs come up a lot more in device companies, especially orthopedic companies, where a surgeon will learn how to use a particular sort of hip or knee replacement, and then it's very costly
property and close relationships with orthopedic surgeons. Zimmer 's acquisition of Biomet removes ..... through, which would still leave Zimmer in a strong leadership position in the orthopedic market. With Zimmer 's new heft and access to the
The most severe downgrade was made to Zimmer 's ZMH "> ZMH credit rating, which ..... billion in net debt. Excluding synergies, Zimmer 's debt/EBITDA will rise to about 4 ..... about 2018, which informs our rating. If Zimmer can deleverage more quickly than that